After two consecutive years of declining performance, Berry Genomics Co.Ltd(000710) recently received an inquiry letter from the annual report of Shenzhen Stock Exchange, which focused on a series of questions such as the authenticity of the company’s early performance.
On May 19, the company explained a number of specific reasons in the reply letter. However, the reporter noted that in recent years, Berry Genomics Co.Ltd(000710) accounts receivable have increased year by year, bringing hidden worries. Among them, the two major customers contribute a lot of income to the company, and the accounts receivable of the company to the two major customers are high.
Last year, Berry Genomics Co.Ltd(000710) the bad debt provision method of accounts receivable of Hunan Jiahui, one of the major customers, was adjusted from combination provision to individual provision, resulting in a significant increase in the bad debt provision of the company. The reporter noted that in recent years, the collection coefficient of Hunan Jiahui (collection in the current period / (balance receivable in the previous period + amount incurred in the current period)) has decreased year by year, from 61.37% in 2018 to 26.07% in 2021.
